Dow Jones 0.00 +0.00 6:31 am PST, February 13, 2007 NASDAQ 2450.38 +0.00 For info, visit access.smallcapnetwork.com S & P 500 0.00 +0.00 Change your subscription status here Russell 2000 805.79 +0.00 VOLUME 07: ISSUE 17 BOCX is on the Runway, Fueled by Cancer Test News Do you think there's a market for a cancer screening test that could be performed and interpreted in a matter of minutes? Better yet, what if it could all be done at the doctor's office during a routine visit? Considering there's nothing else that easy and quick in use right now, we'd have to say it sounds like a great - and potentially profitable - idea.  It appears the brains behind BioCurex's (OTCBB: BOCX) RECAF cancer marker are thinking the same thing.  For anybody new to the SmallCap Network Newsletter, BioCurex's development so far of its RECAF (TM) cancer marker has shown fantastic laboratory results in early detection of prostate, stomach, breast, cervical, colon, and lung cancers, with possibly more cancers being targeted in the future. That's not even the big deal though....the part that blows us away are the improved results over current tests BioCurex is reporting in their detection trials.  Take for instance the PSA test currently used to detect most prostate cancers today. According to competitive data from BioCurex, only about 1/3 of 'positive' PSA test results actually indicate cancer (the other 2/3 of the 'positives' are false positives). Even worse, up to half of 'negative' PSA test results actually should be positives (as the patient really does have cancer, despite the test saying they don't). BioCurex's laboratory testing of RECAF, on the other hand, has shown 90% accuracy when used to detect prostate cancer. Other RECAF testing has detected 92% of cervical cancers, where current pap smear tests are said to only detect 55%-80% of cervical cancers.  No need to detail every single test - the point we're trying to make is this....so far, the RECAF tests being developed sure look much more effective than the alternatives currently in use. In short, we think the technology is more than enough of an improvement to continue to make good progress towards commercialization.  But here's the rub - to achieve that sort of incredible accuracy, the test will have to be processed in a laboratory. It's still a reasonable trade-off, we'd say, but what if there was some sort of an interim cancer screening test? You know, one that could still potentially take advantage of RECAF's efficacy, but also be performed at the doctor's office within a matter of minutes, circumventing the delay and expense associated with lab work.  Well, BioCurex just announced some pretty interesting news to that end. Keep reading.    A Big Step Forward While the clinical laboratory version of the test continued to undergo development during the latter part of last year, it looks like BioCurex has also been working on a faster and easier version of the RECAF test to be used during a patient visit to the doctor.  Commonly called the 'point of care' within the industry, if it works as hoped, a single drop of blood could quickly tell a doctor or nurse whether or not a particular patient should be further tested with a more powerful lab version of a cancer test. As the company describes in the press release below, it would be quite comparable to a pregnancy test or blood sugar monitor.  A couple of key points may need to be made.  First, obviously a test that only costs a few bucks (BioCurex used $5 as a hypothetical price) isn't going to be as accurate as the full-blown laboratory version. However, it doesn't necessarily have to be, as long as it's able to yield meaningful results. The company intends for this to be an easy and effective way for any patient to be preemptively tested, whether or not cancer is suspected. A follow-up confirmation test will still be needed. So, it's not likely to cannibalize the laboratory version of the RECAF test.  Second, the ultimate goal is to license the test technology. This will allow the company to reap royalty fees, while allowing someone else to do the heavy lifting, so to speak. BioCurex has already teamed up with Abbott Laboratories (NYSE: ABT) in the development of the laboratory version of the RECAF test, so we're assuming they'd be a willing partner for this front-line test as well. However, the cool part about this new test is how there's no limitation on who or how many licensees could get involved (well, it's cool because of that and the fact that an effective point-of-care cancer test would be a much-needed answer to a currently unmet need).  Given what we know about BioCurex, RECAF, and the need for such a screening tool, we have to think the potential of this test makes for an incredible trading opportunity. Remember, as we've said before, we think you own companies for where they could go in the future - not for where they are now. According to the company's calculations (in the press release), this may be an annual market worth $1 billion. Even a small sliver of that pie could be enormous for BioCurex and its investors.  Now, don't misread anything here....the test is still in the early development stages, and there's not any particular guarantee it will ever get to the market. And if it does, it may not be until later this year or early next year before it does, depending on how the R&D process takes shape over the next few months.  You know what though? We don't think it really matters, as far as traders or investors are concerned. In fact, it looks like others are already thinking along our same bullish lines, which we feel explains the recent 'perking up' of BOCX shares. We'd also say now that the news is officially out, the stock has a very good chance at practically taking flight. It almost goes without saying we think owning this stock soon - perhaps today - is critical if you want to reap the most reward from the sheer potential of this new use of the RECAF technology.  With that being said, you know we already like BioCurex as an investment...we've been following the company since late 2003 when the stock was trading at 17 cents. Today is just one more reason we have to bang the drum. The RECAF technology looks like a winner to us, and we just have to believe investors are going to be rewarded down the road.  And after today, we feel any reward could come sooner than most people had even thought about. While you're already seeing a big surge in BOCX's trading level, in our opinion, we think the stock could be pressed higher for quite some time based on the news.    General Electric, Abbott, & BioCurex - Sorting It All Out By the way, many of you have been asking questions about how the sale of some Abbott divisions to General Electric (NYSE: GE) could effect BioCurex. The answers are (1) yes, the division BioCurex works with was indeed one the enterprises placed into GE's hands, and (2) no, it's not anticipated that this will disrupt the work and partnership previously put in place by Abbott and BioCurex. In fact, the buzz is, the RECAF project (as well as the other projects that division was working on) is being assertively pushed by the new management at least as firmly as it was under the previous leadership.  Perhaps even more reassuring, we've heard Abbott's equipment is getting good results in trials of BioCurex's RECAF detection test. Remember, the cancer test was only converted to the more common chemoluminescent (light-based) format a few months ago, as you may recall from our October 25, 2006 issue. Why? Colorimetric equipment is becoming the standard in diagnostics; Abbott won't use any kind of immunoassays except for the chemoluminescent kind. We think hearing BioCurex's new colorimetric immonoassays are working well in Abbott's equipment is just a huge step in the right direction, for the company as well as for investors. We'll update you on its progress as soon as we can.  In the meantime, check out the details on today's news:    Press Release  Source: BioCurex, Inc.  BioCurex Begins Development of Unique 'Point-of-Care' Test for Cancer With Estimated Market Size of $1 Billion.  RICHMOND, British Columbia, February 13, 2007. -- BioCurex Inc. (OTCBB:BOCX) announced today that is has started development of a "point-of-care" RECAF test which would be available for use at the doctor's office rather than in a laboratory setting.  During the past two quarters, the Company has been engaged in converting its original radioactive-labelled RECAF blood test for cancer detection into a non-radioactive, colorimetric assay. The information gathered in the format conversion strongly supports the feasibility of a "point-of-care" blood test for cancer detection that could be developed in a relatively short time. "Point-of-care testing" is defined as "Diagnostic testing performed at or near the site of patient care" [1]. A commonly known "Point-of-care" test is available at drug stores for pregnancy determination, but more sophisticated systems, such as the one used for diabetic patients to monitor blood sugars, are also available. The system consists of a lancet to obtain a minute drop of blood, a strip where the blood reacts with the necessary chemicals and a small reader that provides a result in digital form (to view examples of glucose tests and meters go to (http://en.wikipedia.org/wiki/Glucose_meter).  Our patent attorneys have recommended that we do not discuss the technical details of a "point-of-care" RECAF system until we file the corresponding patent(s).  The RECAF "point-of-care" system would be targeted at physicians who either suspect a malignancy at a patient's first visit or are monitoring a patient after cancer treatment. The doctor would carry out the test in their office in a matter of minutes while examining the patient. Given the necessarily lower accuracy of a "point-of-care" test, the device will not "cannibalize" sales of the more precise clinical laboratory tests. Rather, it will orient the physician in the diagnostic procedure and according to the reading, prompt the request of a more accurate test from a laboratory, such as the Company's RECAF serum test. This is similar to the principle whereby a more sophisticated test is utilized to confirm the results of the point-of-care pregnancy tests available in drug stores.  There is no comparable cancer detection test in use. Thus, it is difficult to estimate its potential market size with accuracy. According to the American Medical Association, there were almost 900,000 physicians in the USA in 2004 [2] and a report from the American Academy of Family Physicians called for a 39% increase in the number of practitioners by 2020 to meet demand [3]. Between 1994 and 2004, the number of visits made to physicians grew from 681 million to 910 million per year [4]. New patients accounted for 100 million visits [5]. The number of visits to physician offices and hospital outpatient departments is estimated to be 4-7 per person per year in the 50 years and older age group - where cancer is most prevalent [4]. "Hypertension, malignant neoplasms, acute upper respiratory infection, and diabetes mellitus were the leading illness-related primary diagnoses" [5] (boldface added). 27-37 million visits corresponded to cases in which the physician's primary diagnosis was neoplasm [5], but this number correspond to known cancer cases; whereas the test should be applied to any patient with the suspicion of having a malignancy., and perhaps, for good measure and given the low cost of the assay, to any patient over 50 years of age.  Taking into consideration that there are 100 million visits from new patients each year, we estimate a potential market size for RECAF "point-of-care" tests of 50 million determinations per year in the USA alone. The European Union and Japan combined have twice the population of the USA and therefore it is safe to assume that they represent another 100 million tests. Given the low cost of the test and the possibility that it might be the only RECAF test affordable in many regions, it seems reasonable to allocate another 50 million tests to China, India and the rest of the world. Assuming a price of $5 per test, the estimated potential market would therefore be approximately $1 billion per year.  This type of test is not subject to any exclusive or semi-exclusive contractual limitations and therefore the new test would be available to many potential licensees.  The development of the point of care test using RECAF technology will take time given the need to perfect the technique and instrument design. There is no assurance the Company will be successful in developing this test, or that the market for this test is anywhere near the size estimated. The work done to date has augmented the probability of its completion and the Company is excited at the potential of yet another utilization of RECAF technology for assisting the healthcare of society. We anticipate providing further updates as we move forward with this test and other applications of RECAF technology.  About BioCurex:  BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis, imaging and therapy. The technology identifies a cancer marker known as RECAFtm, which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells. BioCurex has signed a licensing agreement with Abbott Laboratories for BioCurex's RECAFTM Cancer technology as outlined in a joint press release dated March 29, 2005. The release noted that the cancer marker RECAFTM has emerged as a potential biomarker that may be useful in the development of new cancer diagnostics tests. Preliminary studies from the investigators at BioCurex have reported a high level of clinical sensitivity and specificity for RECAF in many of the most common cancers, including prostate, breast, colorectal, lung and others.  To read more about the Company, please visit the News section in our web site (www.biocurex.com).  Note:  The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are "forward-looking statements'' within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results.  Contact:  Ricardo Moro  BioCurex, Inc.  Tel: (604) 207 9150  SOURCES:  1) "Guidelines for point-of-care testing: improving patient outcomes". Kost, GJ. American Journal of Clinical Pathology 1995; 104 (Sup1):S111-S127  2) American Medical Association (http://www.ama-assn.org/ama/pub/category/12930.html)  3) "Report Calls For 39% Increase in Family Physicians", (http://www.aafp.org/online/en/home/press/newskits/20060928/20060928.html) American Academy of Family Physicians  4) "Health, United States, 2005" (http://www.cdc.gov/nchs/data/hus/hus05.pdf). U.S. Department of Health and Human Services Centers for Disease Control and Prevention, National Center for Health Statistics,  5) "National ambulatory Medical Care Survey: 2004 Summary" (http://www.cdc.gov/nchs/data/ad/ad374.pdf). U.S. Department of Health and Human Services Centers for Disease Control and Prevention, National Center for Health Statistics.    We Value Your Feedback   Got comments, questions or suggestions? Send 'em on over: Editor@smallcapnetwork.com If you wish to send a written request or inquiry, please send it to our physical address: TGR Group, LLC 4653 Carmel Mtn Rd Suite 308 #402 San Diego, CA 92130 Commerce Planet Sets Date to Provide Q4 Guidance Ask and you shall receive....sort of. Commerce Planet (OTCBB: CPNE) announced yesterday they'll be providing Q4 earnings guidance on February 22nd. What do we see coming? Strictly conjecture, but here's our logic....  The company has continued to hit record enrollments since we last heard from them in early November. So, we can reasonably assume the trend they had in place last quarter is still in place for Q4 of 2006.  In terms of revenue, the 'Planet' saw $9.7 million in sales in their Q3, with $3.1 million in profits. At the end of Q2 of 2006, they reported sales of $7 million, and they posted sales of $4 million at the end of Q1 from last year. Earnings-wise, over the last three calendar quarters, they saw profits of $0.53 million, $1.4 million, and then $3.1 million in Q3 of 2006.  Rising sales, rising revenues. Need we say more?    Siena's Technology Highlighted By Panasonic What's one of the best ways to get some serious high-quality publicity? We think associating with a high-profile name like Panasonic would sure be one good way. That's exactly what Siena Technologies (OTCBB: SIEN) will be doing in a couple of weeks. In late February through early March, when the Panasonic Company of North America plans to promote their latest DLP and LCD projectors in Las Vegas, Nevada, they'll be using Siena's Race & Sports Book system as the test subject, so to speak.  It's Panasonic's show. However, we actually see Siena being the bigger beneficiary here - Sony may be able to attract a few more eyeballs that Siena may not be able to get in front of otherwise.  Click here for more.    ByIndia's $5 Million Sweepstakes Drives 800% Registration Growth Not that the company needed any help attracting people to the site, but Web2 Corporation's (OTCBB: WBTO) ByIdia.com recently announced an 800% increase in weekly registrations. The vast majority of the increase is being attributed to the site's $5 million sweepstakes, which only began a couple of weeks ago.  Do we even need to reiterate what kind of potential there is here? This particular site is a one-stop destination to provide all sorts of Web 2.0 services. Already the #1 search engine specifically designed for the Indian market, it appears as if ByIndia intends to virtually 'own' the Internet in the world's fourth biggest population of Internet users in the world (and likely to be the biggest by 2010).    Challenger Powerboats Featured In Another Industry Magazine  Just a few days after getting a nice mention in Powerboat Magazine, Challenger Powerboats (OTCBB: CPWB) is slated to appear in Hot Boat Magazine. Same drill as before - more eyeballs on the product could eventually mean more eyeballs drawn to showrooms. This is just great publicity for Challenger, and re-enforces the rebuilding theme we see playing out in 2007. Folks, CPWB shares are up 150% in about two weeks, but we still see some upside potential left. If you like the turn-around story as much as we do, we think owning some is easily merited.  Subscribe Information is power and timely information is profitable. Become informed and profit from Small Cap Network Profiles and Trading Alerts by becoming a Preferred Member today. There is no cost associated with your email subscription. Add your email address below and make sure to check your email inbox and confirm your opt-in request to start receiving the Small Cap Network Email Newsletter on a regular basis. To ensure newsletter delivery, you can add any additional email addresses you may have to the Small Cap Network Member List. Receiving the Small Cap Network Newsletter in multiple locations is the best way of making sure you don't miss the next investing or trading opportunity! For web based email addresses, the Small Cap Network recommends @yahoo.com or @aol.com for timely and reliable email newsletter delivery. Subscribe Here Note: Your email address will be kept strictly confidential, and will not be shared with any other entity for any purpose at any time. If you no longer wish to receive the Small Cap Network Newsletter, simply follow the instructions located at the bottom of every Small Cap Network Newsletter Edition. Unsubscribe Here D I S C L A I M E R: The Small Cap Network, its website and email newsletter (hereafter, cumulatively referred to as "SCN") , is an independent electronic publication committed to providing its readers with factual information on select publicly traded companies. SCN is owned and operated by TGR Group, LLC ("TGR"). TGR is not a registered investment advisor or broker-dealer. All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward maximizing the upside potential for investors while minimizing the downside risk, whenever possible.  Moreover, as detailed below, TGR accepts compensation from third party consultants and/or companies, which it features in the publication and circulation of SCN. To the degrees enumerated herein, SCN should not be regarded as an independent publication.  Click Here or go to http://access.smallcapnetwork.com/compensation_disclosure.html to view our compensation on every company we have ever covered, or visit the following web address: http://access.smallcapnetwork.com/profile_disclosure.html for our full profiles and http://access.smallcapnetwork.com/short_term_alerts.html for Trading Alerts.  TGR Group, LLC has been paid a fee of $25,000 cash and 75,000 shares of newly issued restricted stock by Web2 Corp. for coverage of the Company. TGR Group LLC has been paid a fee of $30,000 and 200,000 newly issued restricted shares of Siena Technologies for coverage of the company. In addition, one of the principles of TGR Group LLC is also a principle of MarketByte LLC. In a separate contractual relationship in 2003, MarketByte LLC was paid a fee of $25,000 in cash and 500,00 newly issued, restricted shares by Siena Technologies for coverage of the company. The term of MarketByte's obligation to Siena Technologies has expired. The aforementioned 500,000 shares issued to MarketByte LLC have become free trading, and whatever number remains could be sold at anytime. This should be viewed as a potential conflict of interest. TGR Group LLC has been paid a fee of $60,000 by Commerce Planet for coverage of the company. In addition, one of the principles of TGR Group LLC is also a principle of MarketByte LLC. In a separate contractual relationship in 2004, MarketByte LLC was paid a fee of $25,000 in cash and 750,000 newly issued, restricted shares by Commerce Planet for coverage of the company. The aforementioned shares are all currently eligible to be free trading. The term of MarketByte's obligation to Commerce Planet has expired. TGR Group LLC has been paid a fee of $25,000 cash and 500,000 shares of newly issued restricted stock directly by Challenger Powerboats for coverage. The aforementioned shares have become free trading under Rule 144. On March 7, 2006, TGR Group LLC entered into a contract extension whereby TGR could receive as much as $65,000 cash and 1 million, newly issued restricted shares over the next one year period from Challenger Powerboats for coverage of the company. To date, TGR has received an additional $35,000 and 500,000 newly issued restricted shares. In October of 2003, TGR Group LLC was paid a fee of $25,000 and one million newly issued restricted shares by Biocurex for coverage of the Company. Under SEC Rule 144, all one million issued restricted shares have been eligible for sale into the public market since October of 2004. In addition, on March 22, 2005, TGR entered into an extended agreement with Biocurex for a fee of 25,000 newly issued restricted shares and on July 1, 2006 TGR entered into another extended agreement with Biocurex for an additional 100,000 shares of newly issued, restricted stock. From time to time TGR sells shares received as compensation for coverage of client companies. Shares received are sold in the open market. Since the shares are received as compensation for services as previously disclosed, and not for investment purposes, TGR does not view the sale of the shares as contradictory to any opinions delivered in the content. This should be viewed as a conflict of interest by shareholders or prospective shareholders of the client companies.  TGR, its Members and Members' families, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication unless specifically disclosed.  All statements and expressions are the sole opinions of TGR and are subject to change without notice. A profile, description, or other mention of a company within SCN is neither an offer nor solicitation to buy or sell any securities mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.  THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN CONSENT OF TGR.  We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission ("SEC") at http://www.sec.gov and/or the National Association of Securities Dealers ("NASD") at http://www.nasd.com. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at http://www.sec.gov/consumer/cyberfr.htm. Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.